#South Korea #Samsung Biologics #Incheon #LigaChem Biosciences #ADC Development

Samsung Biologics Expands Collaboration with LigaChem Biosciences

In an impressive move signaling growth in the biotechnology sector, Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), has announced an extension to its existing collaboration with LigaChem Biosciences. This initiative aims to bolster the development of antibody-drug conjugates (ADCs), a class of targeted cancer therapies. The announcement reflects both companies' commitment to advancing the capabilities required in the realm of ADCs, particularly in the treatment of solid tumors.

The renewed partnership will see Samsung Biologics providing its ADC services from its newly established dedicated facility. This advanced setup is a testament to their collaborative efforts, ensuring that innovative therapies can be developed and brought to market efficiently. LigaChem Biosciences has established itself as a trailblazer by focusing on the research and development of ADC candidates. Their pioneering work in this area complements Samsung Biologics' well-established expertise in biopharmaceutical manufacturing.

John Rim, CEO and President of Samsung Biologics, expressed enthusiasm about the collaboration, stating, "The latest cooperation will further fortify Samsung Biologics' capabilities across all ADC development and manufacturing stages. Our focus remains firmly on delivering therapeutics that are safe and of the highest quality for patients in need. We are dedicated to supporting our clients' innovative ADC pipelines while ensuring timely and quality output."

Moreover, Yong-Zu Kim, President and CEO of LigaChem Biosciences, acknowledged the significance of this partnership, noting that it represents crucial progress toward enhancing the supply chain for high-quality ADC drugs. He emphasized that the synergy between the companies would accelerate the development of LigaChem's pipeline while enabling faster access to innovative ADC treatments for patients.

Samsung Biologics' dedicated ADC facility features a segregated suite equipped with a 500-liter reactor designed to support the intricate processes involved in developing and manufacturing ADC therapies. This specialized facility capitalizes on Samsung’s previous success in large-scale antibody manufacturing and advanced process engineering. The ADC service spectrum provided by the company encompasses the entire process from late discovery to development and conjugation, showcasing their comprehensive capabilities in addressing client needs across multiple phases of drug development.

In addition to the collaboration with LigaChem, Samsung Biologics has continued to actively invest in the biotechnology sector. Through the Samsung Life Science Fund, they are supporting biotechnology companies that are innovating in ADC linker technologies, a cornerstone for the effective functionality of antibody-drug conjugates.

About Samsung Biologics

Samsung Biologics operates as a fully integrated service provider within the CDMO space, delivering seamless development and manufacturing solutions that extend from cell line development through final aseptic fill/finish procedures. Their facilities are fully compliant with CGMP standards and feature bioreactors capable of supporting diverse scales of production, adapting to various client requirements. With a commitment to operational efficiency and a strategic vision to meet the escalating demands of biomanufacturing, Samsung Biologics aims to expand capacity further through upcoming developments, including Bio Campus II, which is set to be operational by April 2025.

About LigaChem Biosciences

LigaChem Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines. Their approach utilizes medicinal chemistry expertise to enhance the targeting and efficacy of traditional biologics, addressing urgent medical needs in fields such as oncology, antibiotics, and anti-fibrotic therapies. As both companies continue to enhance their collaborative initiatives, the potential for advancing patient care through ADC technologies looks promising, positioning them as key players in the competitive healthcare landscape.

For further insights or inquiries, visit Samsung Biologics - ADC Services and LigaChem Biosciences.